Segment Information

12 Months Ended

Dec. 31, 2016

Segment Information

Segment Information

3. Segment Information

        We operate in a single segment, which is the discovery (research), development and commercialization of human therapeutics. The following table summarizes total revenue by geographic region:

	Year Ended December 31,
(In thousands)	2016		2015		2014
U.S.	$	33,179	$	16,981	$	4,231
Europe		15,211		21,354		7,456
Asia		254		2,902		—
Other		4		889		1
Total revenue	$	48,648	$	42,126	$	11,688

        The following table summarizes total revenue from each of our customers or collaboration partners who individually accounted for 10% or more of our total revenue (as a percentage of total revenues) during the most recent three years:

(% of total revenue)	Year Ended December 31, 2016
Mylan		31	%
Takeda		31	%

(% of total revenue)	Year Ended December 31, 2015
Mylan		46	%
Trek Therapeutics		20	%

(% of total revenue)	Year Ended December 31, 2014
Clinigen		43	%
R-Pharm		19	%